Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Passage Bio, Inc. (PASG)  
$1.33 0.16 (10.47%) as of 4:30 Tue 5/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 45,530,000
Market Cap: 60.33(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.6 - $1.73
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 1,192,577 1,192,577
Total Buy Value $0 $0 $1,001,765 $1,001,765
Total People Bought 0 0 1 1
Total Buy Transactions 0 0 2 2
Total Shares Sold 0 45,406 56,859 65,593
Total Sell Value $0 $41,507 $51,586 $62,246
Total People Sold 0 3 4 6
Total Sell Transactions 0 5 6 9
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 61
  Page 3 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Kapadia Sandip Director   –       •      –    2020-03-03 4 B $18.00 $90,000 D/D 5,000 5,000 2.39 14%     
   Woiwode Thomas Director   –       •       •   2020-03-03 4 A $0.00 $0 I/I 4,734,769 708,352     -
   Morris Richard Steven Chief Financial Officer   •       –      –    2020-03-03 4 B $18.00 $7,200 D/D 400 400 2.74 14%     
   Goldsmith Bruce A CEO and President   •       •      –    2020-03-03 4 B $18.00 $19,800 D/D 1,100 1,100 2.81 14%     
   Quigley Jill M. Chief Operating Officer   •       –      –    2020-03-03 4 B $18.00 $18,000 I/I 1,000 1,000 1.99 14%     
   Quigley Jill M. Chief Operating Officer   •       –      –    2020-03-03 4 B $18.00 $27,000 D/D 1,500 311,494 2.74 14%     
   Woiwode Thomas Director   –       •       •   2020-03-03 4 B $18.00 $4,050,000 I/I 225,000 933,352 2.25 14%     
   Woiwode Thomas Director   –       •       •   2020-03-03 4 A $0.00 $0 I/I 708,352 708,352     -
   Woiwode Thomas Director   –       •       •   2020-03-03 4 A $0.00 $0 D/D 4,026,417 4,026,417     -
   Cale Edgar B. GC and Corporate Secretary   •       –      –    2020-03-03 4 B $18.00 $36,000 D/D 2,000 2,000 2.74 14%     
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2020-02-28 4 B $18.00 $6,719,400 I/I 373,300 373,300 1.5     -

  61 Records found
  1  2  3    
  Page 3 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed